PMPedro Iughetti Morais

Pedro Iughetti Morais

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Iughetti Morais has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of caffeine for managing apneia of premature

    by José de Ribamar Barroso Jucá Neto, Lívia Fontelles Brasil, Letícia Martins de Mendonça, Thiago Rocha Mapurunga, Emanuelle Cordova de Souza, Pedro Iughetti Morais, Ângela Rocha Mapurunga

    Apnea of prematurity is a common diagnosis in neonatal intensive care units, especially in preterm patients under 35 weeks or patients born with low birth weight (<1500g). From this perspective, the use of caffeine citrate has short and long-term benefits in this pathology, in addition to reducing the incidence of complications. Methodology: A narrative review of the literature was carried out using the PUBMED database, using the following keywords: “Apnea Prematurity”, “Caffeine” and “Treatment”, with a 6-year filter, analyzing 164 articles, of which only 34 were included and 130 were excluded. Results and Discussion: Apnea of prematurity is a common pathology in preterm and extremely preterm infants, with an incidence of 10% of newborns after 34 weeks and 20-85% of newborns born between 30-34 weeks. The pathophysiology of the disease is explained by the immaturity of the central nervous system in maintaining respiratory drive, in addition to impaired sensitivity in response to chemoreceptors and difficulty in maintaining REM sleep, in addition to the chronic losses inherent to chronic hypoxia. Methylxanthines, the active ingredient in caffeine, have the activation mechanism of inhibiting adenosine A1 and A2 receptors coupled to G protein. The recommended initial dose for therapy is 10 mg/kg for apnea of prematurity, but it must be monitored with concentrations serum levels of the drug to a safe therapeutic range, in addition to monitoring side effects in view of the patient's clinical impairment. The main signs of side effects from the use of caffeine are tachycardia, hyperglycemia, reduced growth rate, jaundice, irritability, agitation and convulsions. Conclusion: Apnea of prematurity is a very prevalent pathology in preterm newborns and its therapeutic possibility must be taken into account in view of its possible short and long-term complications, since the use of methylxanthines has different evidence of clinical improvement. Introducción: La apnea del prematuro es un diagnóstico común en las unidades de cuidados intensivos neonatales, especialmente en pacientes prematuros menores de 35 semanas o pacientes nacidos con bajo peso al nacer (<1500g). Desde esta perspectiva, el uso de citrato de cafeína tiene beneficios a corto y largo plazo en esta patología, además de reducir la incidencia de complicaciones. Metodología: Se realizó una revisión narrativa de la literatura utilizando la base de datos PUBMED, utilizando las siguientes palabras clave: “Apnea Prematurity”, “Caffeine” y “Treatment”, con un filtro de 6 años, analizando 164 artículos, de los cuales solo 34 fueron incluidos y 130 excluidos. Resultados y Discusión: La apnea del prematuro es una patología común en los recién nacidos prematuros y extremadamente prematuros, con una incidencia del 10% de los recién nacidos después de las 34 semanas y del 20-85% de los recién nacidos entre las 30-34 semanas. La fisiopatología de la enfermedad se explica por la inmadurez del sistema nervioso central para mantener el impulso respiratorio, además de la alteración de la sensibilidad en respuesta a los quimiorreceptores y la dificultad para mantener el sueño REM, además de las pérdidas crónicas inherentes a la hipoxia crónica. Las metilxantinas, ingrediente activo de la cafeína, tienen el mecanismo de activación de inhibición de los receptores de adenosina A1 y A2 acoplados a la proteína G. La dosis inicial recomendada para el tratamiento es de 10 mg/kg para la apnea del prematuro, pero debe controlarse con concentraciones séricas. niveles del medicamento a un rango terapéutico seguro, además de monitorear los efectos secundarios en vista del deterioro clínico del paciente. Los principales signos de efectos secundarios del uso de cafeína son taquicardia, hiperglucemia, reducción de la tasa de crecimiento, ictericia, irritabilidad, agitación y convulsiones. Conclusión: La apnea del prematuro es una patología muy prevalente en los recién nacidos prematuros y se debe tener en cuenta su posibilidad terapéutica ante sus posibles complicaciones a corto y largo plazo, ya que el uso de metilxantinas tiene diferentes evidencias de mejoría clínica. Introdução: A apnéia da prematuridade é um diagnóstico comum em unidades de cuidados intensivos neonatais, especialmente, em pacientes pré-termos menores de 35 semanas ou pacientes que nasceram com baixo peso (<1500g). Nessa perspectiva, o uso do citrato de cafeína apresenta benefícios a curto e longo prazo nessa patologia, além de reduzir a incidência de complicações. Metodologia: Foi realizada uma revisão narrativa da literatura com base de dados no PUBMED banco de dados, utilizando as seguintes palavras-chave: “Apnea Prematurity”, “Caffeine” e “Treatment”, com o filtro de 6 anos, sendo analisados 164 artigos, dos quais apenas 34 foram incluídos e 130 foram excluídos. Resultados e Discussão: A apneia da prematuridade é uma patologia comum em pré-termos e pré-termos extremos com incidência de 10% dos neonatos após 34 semanas e 20-85% nos neonatos nascidos entre 30-34 semanas. A fisiopatologia da doença é explicada pela imaturidade do sistema nervoso central em manter drive respiratório, além de prejuízo na sensibilidade de resposta à quimiorreceptores e dificuldade de manutenção do sono REM, além dos prejuízos crônicos inerentes à hipóxia crônica. As metilxantinas, princípio ativo da cafeína, tem como mecanismo de ativação inibir os receptores de adenosina A1 e A2 acoplados à...


  • Open Access

    Treatment of complicated bacterial pneumonia in children

    by Tayná de Freitas Freire, Emanuelle Cordova de Souza, José de Ribamar Barroso Jucá Neto, Manuella Mendonça da Silva, Pedro Iughetti Morais, Yasmim Cavalcante Sousa, Caio César Otôni Espíndola Rocha

    Introduction: Community-acquired pneumonia (CAP) is one of the most common infectious diseases in pediatrics, and may be related to the direct occurrence of local complications such as empyema, necrotizing pneumonia, lung abscess or pleural effusion, which are directly related to worsening of the clinical aspect and prolongation of the hospitalization period. Methodology: A narrative review of the literature was carried out in the PUBMED database, using the following keywords: “Bacterial pneumonia in children”, “Complicated Pneumonia” and “Treatment”, with the time filter for the last 5 years (2019-2023). Results: From the research carried out, 408 articles were identified, of which, after applying inclusion and exclusion criteria, 12 were selected for analysis. Discussion: The main complications are related to specific complementary exams and assertive surgical or antimicrobial therapies that seek to avoid mortality, exacerbation of other complications and reduce hospitalization time and associated morbidities. Conclusion: Knowledge about the complications of community-acquired pneumonia, particularly its course of development and its propaedeutic approach, helps to alleviate the difficulties of the clinical context and provide more security to the doctor in his/her healthcare assistance to the patient.


  • Open Access

    Consumption and level of knowledge about electronic cigarettes among medical students

    by Isadora Mônica Ponte de Oliveira, Alan Bessa Aguiar, Sofia Dantas Pinto Monteiro, José de Ribamar Barroso Jucá Neto, Francisco Glauco de Azevedo Carvalho Filho, Manuella Mendonça da Silva, Bianca Melo de Santana, Brayon Freire Blanquett Vidal, Luiza Targino Studart, Pedro Iughetti Morais, et al.

    Objectives: Considering the increased prevalence of electronic cigarette use and its consequences on the health of users, this study was designed to evaluate the use and knowledge of EC among medical students at a university center in Northeastern Brazil. Methods: This is a cross-sectional observational study, in which sociodemographic data were collected through questionnaires applied to medical students from the first to the twelfth semester. Results: The survey included the participation of 248 students. It was observed that 25 undergraduates (10.1%) claimed to have high understanding about EC, 116 (46.8%) reported to have medium understanding, and 94 (37.9%) low level of knowledge. Furthermore, more than half of the students (53.2%) have already made use of the device. Of these, 38.7% reported vaporizing eventually and 14.5% vaporized daily. Conclusion: Therefore, we highlight the importance of an earlier and more complete approach about the harms of EC to undergraduate medical students to make them partners in the dissemination of information to lay people, including students from other courses and patients.